Literature DB >> 16550556

Is surgery-only the adequate treatment approach for T2N0 rectal cancer?

Sven Petersen1, Gunter Hellmich, Katharina von Mildenstein, Gerhard Porse, Klaus Ludwig.   

Abstract

BACKGROUND AND OBJECTIVES: Resection combined with standard lymphadenectomy is generally recommended for T2N0 rectal cancer. In order to evaluate the outcome of this specific tumor category, our own data were reviewed.
METHODS: To evaluate the results of patients with curative resected T2N0 rectal carcinoma, we reviewed data of 164 consecutive patients with adenocarcinoma of the rectum between 1981 and 2003 in our department. In addition, patient characteristics were stratified according to the position of the rectal tumor with respect to the anal verge.
RESULTS: One hundred ten patients (67.1%) underwent anterior resection and 54 patients (32.9%) received abdominoperineal amputation. The follow-up revealed 6 local recurrences (3.7%); in 10 patients (10.0%), metastases were discovered. Regarding the tumor localization nearly no local recurrence or distant metastases were observed in the middle or the upper rectum. However, in the lower rectum the actuarial 5-year recurrence rate was 16.2%.
CONCLUSIONS: Although T2N0 rectal carcinomas are considered as low risk tumors, we found a considerable local recurrence rate of 3.7%. The question arises whether this result can be improved by adjuvant treatment modalities without being compromised by the toxicity of an adjuvant treatment. (c) 2006 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2006        PMID: 16550556     DOI: 10.1002/jso.20452

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  4 in total

1.  Patterns of failure and survival for nonoperative treatment of stage c0 distal rectal cancer following neoadjuvant chemoradiation therapy.

Authors:  Angelita Habr-Gama; Rodrigo O Perez; Igor Proscurshim; Fábio G Campos; Wladimir Nadalin; Desiderio Kiss; Joaquim Gama-Rodrigues
Journal:  J Gastrointest Surg       Date:  2006-12       Impact factor: 3.452

2.  Management of distal rectal cancer: results from a national survey.

Authors:  G Melotti; E De Antoni; A Habr-Gama; A Minicozzi
Journal:  Updates Surg       Date:  2013-01-19

3.  Optimizing adjuvant treatment decisions for stage t2 rectal cancer based on mesorectal node size: a decision analysis.

Authors:  Rebecca I Hartman; Connie Y Chang; Jennifer Y Wo; Jonathan D Eisenberg; Theodore S Hong; Mukesh G Harisinghani; G Scott Gazelle; Pari V Pandharipande
Journal:  Acad Radiol       Date:  2012-09-02       Impact factor: 3.173

4.  Adjuvant Radiation Survival Benefits in Patients with Stage 1B Rectal Cancer: A Population-based Study from the Surveillance Epidemiology and End Result Database (1973-2010).

Authors:  Abdul Waheed; Frederick D Cason
Journal:  Cureus       Date:  2019-12-05
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.